文献速递胸部肿瘤

RET融合阳性非小细胞肺癌对选择性RET酪氨酸激酶抑制剂的耐药机制

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2020-09-29

该多中心研究分析了18例接受selpercatinib或pralsetinib治疗的RET融合阳性NSCLC患者的23份治疗后组织/血浆样本,中位PFS为6.3个月。获得性RET G810溶剂前沿突变见于2例(10%),MET扩增见于3例(15%),KRAS扩增见于1例,无组织学转化。耐药多由RET非依赖性机制驱动,需开发强效RET抑制剂及联合策略。

要点

  • RET溶剂前沿突变是耐药机制但频率较低(10%)。
  • MET扩增(15%)和KRAS扩增是主要RET非依赖性耐药机制。
  • 未见鳞状或小细胞组织学转化。

核心结论

  • RET溶剂前沿突变是选择性RET抑制剂耐药的复发性机制但频率较低。
  • 多数耐药可能由RET非依赖性机制如获得性MET或KRAS扩增驱动。
  • 需要强效针对RET耐药突变的新一代RET抑制剂及联合策略以克服耐药。

研究设计与样本

  • 在五个机构开展的研究,纳入18例RET融合阳性NSCLC患者。
  • 收集selpercatinib或pralsetinib治疗后的组织或cfDNA样本,共23份活检。
  • 采用NGS或MET FISH检测耐药机制。

主要发现

  • RET抑制剂中位无进展生存期为6.3个月(95%CI 3.6-10.8个月)。
  • 2例(10%)检出获得性RET突变,均影响RET G810残基(激酶溶剂前沿)。
  • 3例(15%)耐药病例存在获得性MET扩增且无 concurrent RET耐药突变。
  • 1份标本检出获得性KRAS扩增。
  • 16份耐药肿瘤标本中无一例有鳞状或小细胞组织学转化证据。

临床怎么用

  • 对选择性RET抑制剂耐药患者应进行NGS检测以明确RET依赖性及非依赖性耐药机制。
  • 检出MET或KRAS扩增提示可考虑相应靶向联合策略。
  • RET G810溶剂前沿突变患者可能需要新一代RET抑制剂。

局限性

  • 样本量较小(18例患者,23份活检)。
  • 仅部分病例有配对组织与血浆样本。
  • 耐药机制谱可能未完全覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. Insights into mechanisms of resistance to selective RET inhibitors remain limited. PATIENTS AND METHODS: This study was performed at five institutions. Tissue and/or cell-free DNA was obtained from patients with RET fusion-positive NSCLC after treatment with selpercatinib or pralsetinib and assessed by next-generation sequencing (NGS) or MET FISH. RESULTS: We analyzed a total of 23 post-treatment tissue and/or plasma biopsies from 18 RET fusion-positive patients who received an RET-selective inhibitor (selpercatinib, n = 10; pralsetinib, n = 7; pralsetinib followed by selpercatinib, n = 1, with biopsy after each inhibitor). Three cases had paired tissue and plasma samples, of which one also had two serial resistant tissue specimens. The median progression-free survival on RET inhibitors was 6.3 months [95% confidence interval 3.6-10.8 months]. Acquired RET mutations were identified in two cases (10%), both affecting the RET G810 residue in the kinase solvent front. Three resistant cases (15%) harbored acquired MET amplification without concurrent RET resistance mutations, and one specimen had acquired KRAS amplification. No other canonical driver alterations were identified by NGS. Among 16 resistant tumor specimens, none had evidence of squamous or small-cell histologic transformation. CONCLUSIONS: RET solvent front mutations are a recurrent mechanism of RET inhibitor resistance, although they occurred at a relatively low frequency. The majority of resistance to selective RET inhibition may be driven by RET-independent resistance such as acquired MET or KRAS amplification. Next-generation RET inhibitors with potency against RET resistance mutations and combination strategies are needed to effectively overcome resistance in these patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lin JJ, Liu SV, McCoach CE, et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol. 2020. PMID: 33007380. doi:10.1016/j.annonc.2020.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。